Funding to successfully finalise EDCTP2-funded clinical trials that were negatively impacted by the COVID-19 pandemic
Programme Category
Programme Name
Programme Description
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3) builds on the first and second European and Developing Countries Clinical Trials Partnership programmes. This new joint undertaking (JU) is a partnership between the EU and the EDCTP Association, whose members are several European and African countries. The partnership will deliver new solutions for reducing the burden of infectious diseases in SSA and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.
Identifier Code
Call
Summary
This topic focuses on the clinical trials of medical technologies that were funded by EDCTP2 and whose activities were disrupted during the COVID-19 pandemic.
Information about medical technologies can be used by health care professionals and health care systems.
Detailed Call Description
The clinical trials identified by their clinical trial registration numbers are addressed by this topic.
This funding will ensure that essential clinical trials working to deliver answers of immediate public health relevance in SSA can be concluded. Focussing funding to projects previously supported under the EDCTP2 programme is justified by the advanced stage ongoing studies have reached. It is also justified by ethical issues, such as fully validating the willingness of trial participants to take part in the clinical investigations.
The proposals need to address all of the following:
- Demonstrate the work performed so far, such as number of recruited trial participants, follow-up status as well as analyses to be performed;
- Explain the impact of COVID-19-related delays and disruption in relation to the trial timing (start, recruitment, follow-up period);
- Clearly explain the additional work to be carried out, with a comprehensive plan and budget to conclude the planned studies in a tight timeframe;
- Proposals should present a sound assessment of the feasibility of the planned clinical investigations. Realistic plans for recruiting and following up trial subjects must be presented and corroborated by demonstrated success from previous studies and/or the current study;
- Whilst it is acknowledged that the projects build on previous studies, the proposals should briefly recall the justification of the choice of populations to be enrolled into the trials and explain how they relate to the larger population.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
Expected EU contribution per project: €200 000 – €2 500 000
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Researchers/Research Centers/Institutions
Eligibility For Participation Notes
See page 13-14 of the Annex 1 of the Global Health EDCTP3 Work Programme 2023: call topics.
Call Opening Date
Call Closing Date
EU Contact Point
EDCTP – Europe Office
Postal and visiting address
Anna van Saksenlaan 51
2593 HW The Hague, The Netherlands
Telephone: +31 70 344 0880
EDCTP – Africa Office
Postal address
P.O. Box 19070, Tygerberg 7505
Cape Town, South Africa
Visiting address
Francie van Zijl Drive,
Parowvallei 7505
Cape Town, South Africa
Telephone: +27 21 938 0690
Fax: +27 21 938 0569
Contact Form in the website